Actively Recruiting
Evaluation of the DIALIVE 2.0 Liver Dialysis Device Compared to Standard Care for Acute-on-Chronic Liver Failure Grades 2-4 in a Randomised Controlled Trial
Led by Yaqrit Ltd · Updated on 2026-09-22
72
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the DIALIVE 2.0 Liver Dialysis Device as part of the treatment for adults aged 18 to 70 years with acute-on-chronic liver failure ACLF grades 2 to 4, caused by liver cirrhosis and a recent worsening due to a triggering event. This multicenter, randomized, controlled trial compares standard care alone to standard care combined with DIALIVE 2.0 treatment, aiming to improve resolution of ACLF. The study involves 72 participants across up to 12 clinical centers in the United Kingdom. The trial has two groups one receiving standard care chosen by the investigator, and the other receiving standard care plus up to seven daily sessions of DIALIVE 2.0 within a 10-day treatment window. DIALIVE 2.0 works by filtering the participants blood to remove toxins and endotoxins while replacing functional albumin, using a combination of approved medical devices integrated into a hemofiltration and plasmapheresis system. Each daily treatment lasts six to eight hours and includes administration of fresh frozen plasma to help restore blood clotting balance. Participants will be involved in the study for up to 105 days, which includes a screening period of up to 5 days, the treatment phase lasting up to 10 days, and follow-up monitoring for 90 days. During the study, researchers will assess resolution of ACLF, survival without liver transplant, organ function, time to hospital discharge, and any serious adverse events. All randomized participants are included in the main analysis, and safety monitoring covers all who receive at least one treatment session.
CONDITIONS
Brief Title
A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.
Research Team
C
Carrie Morgan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here